Treatment of cancer is by no means universally successful and often manifests harmful side effects. The best
way to improve the success rate and reduce the side effects would be to develop compounds that are able to kill cancer
cells while leaving normal cells unaffected. In this respect, mitocans (an acronym from ‘mitochondria’ and ‘cancer’), a
summary term we proposed for compounds that induce cell death by targeting mitochondria, show an encouraging trend.
Here we provide an overview of mitocans specific for the mitochondrial electron transport chain. These mitocans are particularly
interesting, because a frequent consequence of electron transport chain inhibition is the induction of superoxide
formation resulting in the preferential killing of cancer cells, as these tend to be more sensitive than normal cells to sudden
increases in oxidative stress. Furthermore, macromolecular complexes of the electron transport chain only rarely mutate in
cancer, and represent useful targets for anti-cancer drug development when widely-applicable agents are sought.
Keywords: Cancer; mitochondria, electron transport chain, oxidative stress, cancer, anti-cancer drug development, tricarboxylic
acid cycle (TCA), ROS formation, target specific
regulatory proteins/pathways, chronic myeloid leukemia
Rights & PermissionsPrintExport
Published on: 27 February, 2013
Page: [377 - 389]